These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36617171)

  • 1. Neutrophil function following treatment of psoriatic arthritis patients with secukinumab: altered cytokine signalling but no impairment of host defence.
    Cross AL; Hawkes J; Frankland H; Mediana A; Wright HL; Goodson NJ; Edwards SW; Moots RJ
    Rheumatology (Oxford); 2023 Sep; 62(9):3025-3034. PubMed ID: 36617171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
    Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
    J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
    Gottlieb AB; Merola JF; Reich K; Behrens F; Nash P; Griffiths CEM; Bao W; Pellet P; Pricop L; McInnes IB
    Br J Dermatol; 2021 Dec; 185(6):1124-1134. PubMed ID: 33913511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis.
    Cardner M; Tuckwell D; Kostikova A; Forrer P; Siegel RM; Marti A; Vandemeulebroecke M; Ferrero E
    RMD Open; 2023 Jun; 9(2):. PubMed ID: 37321668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of secukinumab in psoriasis treatment.
    Berg SH; Balogh EA; Ghamrawi RI; Feldman SR
    Immunotherapy; 2021 Feb; 13(3):201-216. PubMed ID: 33203276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of psoriatic arthritis complicated by systemic lupus erythematosus with the IL-17 blocker secukinumab and an analysis of the serum cytokine profile.
    Sato K; Aizaki Y; Yoshida Y; Mimura T
    Mod Rheumatol Case Rep; 2020 Jul; 4(2):181-185. PubMed ID: 33086998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
    McInnes IB; Sieper J; Braun J; Emery P; van der Heijde D; Isaacs JD; Dahmen G; Wollenhaupt J; Schulze-Koops H; Kogan J; Ma S; Schumacher MM; Bertolino AP; Hueber W; Tak PP
    Ann Rheum Dis; 2014 Feb; 73(2):349-56. PubMed ID: 23361084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.
    Reich K; Papp KA; Matheson RT; Tu JH; Bissonnette R; Bourcier M; Gratton D; Kunynetz RA; Poulin Y; Rosoph LA; Stingl G; Bauer WM; Salter JM; Falk TM; Blödorn-Schlicht NA; Hueber W; Sommer U; Schumacher MM; Peters T; Kriehuber E; Lee DM; Wieczorek GA; Kolbinger F; Bleul CC
    Exp Dermatol; 2015 Jul; 24(7):529-35. PubMed ID: 25828362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
    Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
    Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study.
    Kampylafka E; d'Oliveira I; Linz C; Lerchen V; Stemmler F; Simon D; Englbrecht M; Sticherling M; Rech J; Kleyer A; Schett G; Hueber AJ
    Arthritis Res Ther; 2018 Jul; 20(1):153. PubMed ID: 30053825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab for the treatment of psoriatic arthritis.
    Baronaite Hansen R; Kavanaugh A
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1027-36. PubMed ID: 27550397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of psoriatic arthritis with secukinumab: a case series.
    Nicola S; Rolla G; Monti R; Brussino L
    J Dermatolog Treat; 2018; 29(sup1):6-8. PubMed ID: 30247936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
    McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
    Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of secukinumab in patients with psoriatic arthritis: A meta-analysis of different dosing regimens.
    Zhang KL; Hou SY; Wu D
    Clinics (Sao Paulo); 2021; 76():e2820. PubMed ID: 34614111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis.
    McInnes IB; Nash P; Ritchlin C; Choy EH; Kanters S; Thom H; Gandhi K; Pricop L; Jugl SM
    J Comp Eff Res; 2018 Nov; 7(11):1107-1123. PubMed ID: 30230361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature.
    Abrouk M; Gandy J; Nakamura M; Lee K; Brodsky M; Singh R; Zhu H; Farahnik B; Bhutani T; Koo J
    Skin Therapy Lett; 2017 Jul; 22(4):1-6. PubMed ID: 28732152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab (AIN-457) for the treatment of Psoriasis.
    Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
    Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.